Oruka Therapeutics, Inc. (ORKA) Stock Forecast
ORKA analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.85 / 5 from 13 analysts
- Price target
- $155.00 average of analyst targets
- Upside to target
- +115.5% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $-0.68
- 52-week range
- $26.19 – $113.08
ORKA analyst ratings
13 analystsNumber of analysts at each rating.
ORKA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ORKA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.62 | −$0.79 | −$0.41 | −$0.55 | −12.4% | 9 |
| Current fiscal year (2026) | −$2.37 | −$2.90 | −$1.83 | −$1.85 | −27.9% | 9 |
| Next fiscal year (2027) | −$2.86 | −$4.09 | −$2.19 | −$2.37 | −20.9% | 9 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ORKA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 9 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 9 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 9 |
ORKA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ORKA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.51 | −$0.51 | −$0.62 | −$0.62 | −$0.62 | +22.0% | 1 up · 7 down |
| Current fiscal year (2026) | −$2.04 | −$2.04 | −$2.37 | −$2.37 | −$2.37 | +16.1% | 1 up · 8 down |
| Next fiscal year (2027) | −$2.49 | −$2.49 | −$2.86 | −$2.86 | −$2.86 | +14.8% | 3 up · 6 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ORKA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ORKA beat in 3 of 8.
What analysts expect from ORKA
13 analysts cover Oruka Therapeutics; their consensus rating is strong buy (4.85 on a 1–5 scale, where 5 is a strong buy). The average price target is $155.00, 115.5% above the latest close of $71.93. Analysts expect earnings of −$2.37 per share for 2026, −27.9% from a year earlier. For 2027 the average estimate is −$2.86 per share. Oruka Therapeutics beat the EPS estimate in 3 of the last 8 quarters.
Related: ORKA income statement, ORKA key metrics, ORKA chart. See the ORKA stock overview for the latest quote and news.
ORKA forecast FAQ
What is Oruka Therapeutics's price target?
The average analyst price target for Oruka Therapeutics is $155.00, 115.5% above the latest close of $71.93.
Is Oruka Therapeutics a buy, hold or sell?
Of 13 analysts covering Oruka Therapeutics, 11 rate it a strong buy, 2 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Oruka Therapeutics's EPS forecast?
Analysts forecast −$2.37 per share for 2026 (range −$2.90 to −$1.83); for 2027 the estimate is −$2.86.
When does Oruka Therapeutics report earnings?
Oruka Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 11, 2026 before the market opens; the EPS estimate is $-0.68.
Does Oruka Therapeutics usually beat earnings estimates?
Oruka Therapeutics reported EPS at or above the analyst estimate in 3 of the last 8 quarters.